REDUCTION OF TELOMERES AND CELLULAR GROWTH ARREST
The limited proliferative capacity of normal cells is now thought to be controlled by a generational clock that resides at the chromosome ends, the telomeres. The hexameric sequence, TTAGGG, is repeated several thousand times and comprises what is known as telomeric DNA (8) . Due to the cell's inability to complete the replication of linear DNA [end replication problem (9) ], some telomeric DNA is lost with each cell division. Telomeres thus provide a buffer of expendable, noncoding DNA to accommodate the end replication problem (10) . Telomeres protect chromosome ends from degradation and recombination (11) and also promote correct mitotic separation of sister chromatids (12) . In addition, telomeres serve as a platform for telomere binding proteins (13) . When a critically shortened telomere length is reached, the senescence program is initiated, perhaps via a DNA damage checkpoint pathway (14) . Indeed, there is increasing evidence that the sequential shortening of telomeric DNA may be an important molecular timing mechanism. Correlative evidence in support of this includes the following: 1) Telomeres are shorter in somatic tissues from older individuals when compared with younger individuals (15); 2) telomeres are shorter in somatic (body) tissues than comparable germline (reproductive) cells (16); 3) normal cells generally have longer telomeres than those in tumor cells obtained from the same individual (17); 4) children born with certain early aging syndromes have shorter telomeres than age-matched control subjects (18); and 5) telomeres in normal cells from young individuals progressively shorten when grown in cell culture (19) .
TELOMERASE: A CELLULAR REVERSE TRANSCRIPTASE THAT BYPASSES TELOMERE-BASED CELL GROWTH LIMITATIONS
At birth, telomeres in human cells consist of about 15 000 base pairs of repeated TTAGGG DNA sequences (17) . Every time a cell divides, it loses 25-200 DNA base pairs from the telomere ends (18, 19) . Once this pruning has occurred about 100 times, a cell undergoes senescence and does not continue dividing. Reproductive tissues must have a mechanism to compensate for the progressive telomere erosion, otherwise the species would soon be lost. Nature's solution for germline cells is telomere terminal transferase (telomerase), a ribonucleoprotein reverse transcriptase enzyme (20) (21) (22) . Telomerase uses its RNA component containing an internal template complementary to the telomeric TTAGGG repeats to bind to telomeres. Its catalytic protein component synthesizes telomeric DNA directly onto the ends of chromosomes by the process of reverse transcription of the RNA template (20) (21) (22) (23) (24) (25) (26) . Telomerase is present in most fetal tissues, normal adult male reproductive cells, inflammatory cells, proliferative cells of renewal tissues, and in most tumor cells (27) (28) (29) (30) (31) .
Overall, the telomere/telomerase hypothesis of aging and cancer can be summarized as follows: 1) Progressive telomere loss in all somatic cells including stem cells of renewal tissues is normal and is the ''clock'' or timing mechanism that regulates cellular senescence (32, 33) ; 2) cellular senescence occurs when only a single telomere or perhaps a few telomeres shorten to a critical length; 3) telomerase is repressed in most somatic tissues, and change(s) in the normal telomerase repression pathway cause the enzyme to increase in activity or reactivate; and 4) either telomerase activity or another mechanism to maintain telomere stability in cancer cells is a hallmark of all immortalized cancer cell populations. During the past 3 years, more than 500 papers have been published on the topic of telomerase. These have almost universally shown that telomerase is detected in primary tumors but not in adjacent cleared margins (28) (29) (30) (31) . Importantly, while there is a strong association between the presence of telomerase and cancer, this does not indicate that telomerase is either an oncogene or that it causes cancer (34).
INHIBITING TELOMERASE AS A THERAPY FOR TREATING CANCER
Because telomerase activity is detected in almost all advanced tumors, it is hoped that scientists may be able to develop a therapy that inhibits telomerase activity and interferes with the growth of many types of cancer (35) . Following conventional treatments (surgery, radiotherapy, and chemotherapy), antitelomerase agents would most likely be given to limit the proliferative capacity of the rare surviving tumor cells in the hope that this would prevent cancer recurrence. In addition, telomerase inhibitors could also be used as chemopreventive agents in high cancer-susceptibility individuals or in early stage cancer to prevent overgrowth of metastatic cells.
One important consideration with this proposed treatment regimen is the prolonged time potentially required for a telomerase inhibitor to be effective (Fig. 1) . Since the mode of action of telomerase inhibitors may require further telomeric shortening of cancer cells before inhibition of cell proliferation, there may be a significant delay in efficacy. The combinatorial use of telomerase inhibitors with other cancer therapeutic agents may more effectively achieve complete cancer remissions.
There are also other considerations in the use of such therapy, e.g., the effects of inhibitors on telomerase expressing stem cells. However, it is likely that this approach will be less toxic than conventional chemotherapy that affects all proliferating cells, including stem cells. Studies (36) on pediatric neuroblastoma demonstrate that some tumors without telomerase activity do not continue growing and eventually die. These data add support to the idea that telomerase or another mechanism to provide telomere stability is required to sustain tumor cell growth and that telomerase inhibitors may have efficacy in treating cancer.
EVIDENCE FOR A CHROMOSOME 3 TELOMERASE REPRESSOR
Introduction of a normal chromosome 3, but not chromosome 7 or 11, into a renal cell carcinoma cell line (RCC23) results in telomerase repression and progressive telomere shortening. After 23-43 population doublings, there is cessation of cell growth (37) . Furthermore, the inhibition of cell growth is accompanied by expression of senescence-activated ␤-galactosidase (38) . Importantly, the reduction of telomerase activity is accompanied by a decrease in the abundance of messenger RNA encoding the catalytic protein subunit of telomerase (hTERT). Thus, the telomerase repressor on chromosome 3 may act either directly or indirectly as a transcriptional repressor of hTERT. This not only confirms that hTERT is the rate-limiting determinant of telomerase activity but also provides a direct link between telomerase repression and cellular senescence.
In this issue of the Journal, Cuthbert et al. (39) confirm the importance of a telomerase repressor on chromosome 3. In this study, introduction of a normal human chromosome 3 but not chromosome 8, 12, or 20 into a breast carcinoma cell line (21NT) resulted in telomerase repression followed by permanent growth arrest after 10-18 population doublings. Since the 21NT cells have telomeres that are about 3 kilobases (kb) and the RCC23 have about 6 kb of telomeres, the time of delay until growth arrest is consistent with a progressive telomere shortening, senescence-based mechanism.
There has been additional support for the presence of a telomerase repressor on chromosome 3. For example, Yashima et al. (40) showed that loss of heterozgosity at chromosome 3p occurs very early in the pathogenesis of non-small-cell lung cancer and that this coincides with the detection of telomerase activity in early preneoplastic lesions. Similarly, Mehle et al. The link between shortening of telomeres and cellular aging and that telomeres are stably maintained in cancer cells has prompted intense investigations into the pathways connecting cellular aging and cancer (45) . The medical community is excited by the possibilities that manipulating telomere length could change the rate of cellular senescence and affect the degenerative diseases of aging or that inhibition of telomerase could provide a novel approach to cancer therapeutics. In summary, telomerase may be important in cancer diagnostics (46, 47) , as a target for cancer therapy (35, 47) , and in the treatment of agerelated disease (32, 34) . The challenge is to find out how to make our cancer cells age and stop dividing and our aging but healthy cells continue to divide. Telomerase will likely have many important applications in the future of medicine and cell engineering. Telomeres progressively shorten in all normal somatic cells. With cancer and telomerase reactivation, telomere stability is maintained, generally at shortened lengths. The addition of a telomerase-repressor gene or antitelomerase therapeutic agent would inhibit the activity of the enzyme, leading to progressive telomere shortening with additional cell proliferation in all telomerase-competent cells. After a period of time, the cancer cells should exhibit growth arrest or die, and the use of telomerase inhibitors could be discontinued. The combinatorial use of telomerase inhibitors with angiogenic inhibitors or other cancer therapeutic agents may more effectively achieve complete cancer remissions.
